SCA7 Gene

Migration, Crosslink

📖

SCA7 Gene

active

wiki page Created: 2026-04-02T07:19:19 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-sca7

📖 Wiki Page

gene2779 wordssynced 2026-04-02

SCA7 - ATXN7 (Ataxin-7)

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#f0f0f0; text-align:center;">SCA7</th></tr> [@sca7_nature1993]
<tr><td><b>Full Name</b></td><td>ATXN7 (Ataxin-7)</td></tr> [@atxn7_structure_2006]
<tr><td><b>Chromosomal Location</b></td><td>3p12</td></tr> [@sca7_nature1993]
<tr><td><b>NCBI Gene ID</b></td><td>[6314](https://www.ncbi.nlm.nih.gov/gene/6314)</td></tr>
<tr><td><b>OMIM</b></td><td>[164500](https://www.omim.org/entry/164500)</td></tr>
<tr><td><b>UniProt ID</b></td><td>[Q9UQ50](https://www.uniprot.org/uniprotkb/Q9UQ50/entry)</td></tr>
<tr><td><b>Category</b></td><td>Transcription Factor</td></tr>
<tr><td><b>Protein Length</b></td><td>892 amino acids</td></tr> [@atxn7_isoforms_2024]
<tr><td><b>Inheritance</b></td><td>Autosomal dominant</td></tr> [@sca7_phenotype_2022]
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/ataxia" style="color:#ef9a9a">Ataxia</a>, <a href="/wiki/neurodegenerative-diseases" style="color:#ef9a9a">NEURODEGENERATIVE DISEASES</a>, <a href="/wiki/neurodegeneration" style="color:#ef9a9a">Neurodegeneration</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">5 edges</a></td>
</tr>
</table>
</div>

Overview

...

SCA7 - ATXN7 (Ataxin-7)

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#f0f0f0; text-align:center;">SCA7</th></tr> [@sca7_nature1993]
<tr><td><b>Full Name</b></td><td>ATXN7 (Ataxin-7)</td></tr> [@atxn7_structure_2006]
<tr><td><b>Chromosomal Location</b></td><td>3p12</td></tr> [@sca7_nature1993]
<tr><td><b>NCBI Gene ID</b></td><td>[6314](https://www.ncbi.nlm.nih.gov/gene/6314)</td></tr>
<tr><td><b>OMIM</b></td><td>[164500](https://www.omim.org/entry/164500)</td></tr>
<tr><td><b>UniProt ID</b></td><td>[Q9UQ50](https://www.uniprot.org/uniprotkb/Q9UQ50/entry)</td></tr>
<tr><td><b>Category</b></td><td>Transcription Factor</td></tr>
<tr><td><b>Protein Length</b></td><td>892 amino acids</td></tr> [@atxn7_isoforms_2024]
<tr><td><b>Inheritance</b></td><td>Autosomal dominant</td></tr> [@sca7_phenotype_2022]
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/ataxia" style="color:#ef9a9a">Ataxia</a>, <a href="/wiki/neurodegenerative-diseases" style="color:#ef9a9a">NEURODEGENERATIVE DISEASES</a>, <a href="/wiki/neurodegeneration" style="color:#ef9a9a">Neurodegeneration</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">5 edges</a></td>
</tr>
</table>
</div>

Overview

The SCA7 gene encodes ATXN7 (Ataxin-7), a transcriptional coactivator protein that plays a critical role in chromatin remodeling and gene expression regulation. SCA7 (Spinocerebellar Ataxia Type 7) is one of the polyglutamine (polyQ) expansion diseases, a group of nine autosomal dominant neurodegenerative disorders caused by CAG trinucleotide repeat expansions within the coding region of specific genes [@polyq_toxicity_2011]. The expansion of a polyglutamine tract in the N-terminal region of ATXN7 leads to progressive neuronal dysfunction and death, primarily affecting the cerebellum and retina [@sca7_retinal_2012].

SCA7 is unique among polyglutamine diseases due to its combination of cerebellar ataxia and progressive visual loss from cone-rod dystrophy, a feature not seen in other ataxias [@sca7_cerebellum_2017]. The disease typically presents in the second to fourth decade of life, with earlier onset correlating with longer CAG repeat expansions [@sca7_phenotype_2022].

Gene Structure and Molecular Biology

Genomic Organization

The SCA7 gene (ATXN7) is located on chromosome 3p12 and consists of 13 exons spanning approximately 130 kb of genomic DNA [@sca7_nature1993]. The CAG repeat is located in exon 2, encoding a polyglutamine tract in the N-terminal region of the protein. Normal individuals carry 4-35 CAG repeats, while affected individuals have 36-130 repeats [@sca7_phenotype_2022].

Alternative Splicing

Recent research has identified multiple alternatively spliced isoforms of ATXN7 that generate pathogenic protein variants [@atxn7_isoforms_2024]. These isoforms differ in their N-terminal regions and demonstrate varying levels of toxicity in cellular models. The identification of these isoforms has important implications for therapeutic targeting, as some isoforms may be more amenable to splice-modulating therapies.

Protein Structure

ATXN7 is a 892-amino acid protein with several distinct functional domains [@atxn7_structure_2006]:

Polyglutamine (polyQ) tract: N-terminal region containing the expanded CAG repeat

SAGA interaction domain: Mediates binding to the SAGA coactivator complex

Nuclear localization signal (NLS): Target protein to the nucleus

C-terminal acidic domain: Involved in transcriptional activation

Function in Normal Cells

Role in the SAGA Complex

ATXN7 is a core component of the SAGA (Spt-Ada-Gcn5 acetyltransferase) transcriptional coactivator complex [@atxn7_structure_2006]. The SAGA complex plays essential roles in:

Histone acetylation: Through the GCN5 acetyltransferase activity
Histone deubiquitination: Through the USP22 deubiquitinase activity
Transcriptional activation: By bridging transcription factors with the basal transcriptional machinery

The SAGA complex is evolutionarily conserved and regulates expression of genes involved in development, stress response, and cellular homeostasis [@sags_complex_2018].

Transcriptional Regulation

In neurons, ATXN7 regulates expression of genes critical for cerebellar and retinal function [@transcriptional_dysregulation_2014]. Normal ATXN7 function includes:

Regulation of genes involved in Purkinje cell survival
Control of phototransduction genes in retinal photoreceptors
Modulation of mitochondrial function genes
Maintenance of synaptic plasticity genes

Molecular Mechanisms of SCA7 Pathogenesis

Gain-of-Function Toxicity

The polyglutamine expansion in ATXN7 leads to a toxic gain-of-function [@polyq_toxicity_2011]. The expanded polyQ tract undergoes conformational changes that result in:

Protein misfolding: Formation of β-sheet rich structures

Aggregate formation: Intracellular inclusion bodies

Transcriptional dysregulation: Sequestration of transcription factors

Mitochondrial dysfunction: Impaired energy metabolism

Transcriptional Dysregulation

The mutant ATXN7 protein disrupts normal transcriptional programs through multiple mechanisms [@transcriptional_dysregulation_2014]:

Sequestration of transcription factors: Abnormal protein interactions with TFIID, PCAF, and other coactivators
Altered chromatin accessibility: Dysregulation of histone modifications
Dysregulated gene networks: Loss of normal target gene expression

Patient-derived induced pluripotent stem cell (iPSC) models have demonstrated widespread transcriptional dysregulation, particularly affecting genes involved in mitochondrial function and oxidative stress response [@sca7_patient_ipsc_2015].

Mitochondrial Dysfunction

Multiple studies have demonstrated mitochondrial impairment in SCA7 [@sca7_patient_ipsc_2015]:

Reduced mitochondrial membrane potential
Increased reactive oxygen species (ROS) production
Impaired ATP synthesis
Altered mitophagy

This mitochondrial dysfunction appears to be a central mechanism of neuronal death [@antioxidants_mito_2022].

Protein Aggregation

Like other polyglutamine diseases, SCA7 is characterized by neuronal intranuclear inclusions (NII) containing the mutant ATXN7 protein [@sca7_cerebellum_2017]. These aggregates:

Form in both the cytoplasm and nucleus
May sequester normal proteins including transcription factors
Trigger cellular stress responses
Activate autophagy pathways

Disease Phenotype

Cerebellar Ataxia

The hallmark of SCA7 is progressive cerebellar ataxia [@sca7_cerebellum_2017]:

Gait instability: Progressive gait disturbance beginning in childhood or early adulthood
Limb ataxia: Incoordination of arms and legs
Dysarthria: Slurred speech due to cerebellar dysarthria
Ocular motor abnormalities: Nystagmus, gaze palsy

Pathological studies reveal:

Purkinje cell degeneration: Primary target of pathology
Granule cell loss: Secondary to Purkinje cell death
Inferior olivary nucleus involvement: Contributes to cerebellar dysfunction
White matter tract degeneration: Including climbing fibers

Retinal Degeneration

SCA7 is unique among spinocerebellar ataxias for causing progressive visual loss [@sca7_retinal_2012]:

Cone-rod dystrophy: Primary photoreceptor degeneration
Progressive vision loss: Can lead to legal blindness
Visual field defects: Central and peripheral vision loss
Color vision abnormalities: Early loss of color discrimination

The retinal degeneration is thought to result from:

ATXN7 expression in retinal photoreceptors
Dysregulation of phototransduction genes
Progressive photoreceptor cell death

Other Manifestations

Cardiac involvement: Cardiomyopathy in some patients
Endocrine disorders: Rarely, endocrine dysfunction
Cognitive impairment: Variable, usually mild

Therapeutic Approaches

RNA-Targeting Therapies

Several RNA-targeting approaches are in development [@rna_therapy_2021]:

Antisense oligonucleotides (ASOs): Direct targeting of ATXN7 mRNA

RNAi-based approaches: siRNA-mediated knock-down

Small molecule modifiers: Compounds that reduce CAG repeat translation

Gene Therapy

Viral vector-based approaches are being developed [@gene_therapy_2024]:

AAV-mediated gene silencing: Delivery of shRNA or miRNA
CRISPR-based correction: Direct editing of the CAG repeat [@crispr_correction_2020]
Gene replacement: Expressing truncated non-toxic ATXN7

Epigenetic Therapies

Given the transcriptional dysregulation, epigenetic approaches are being explored [@epigenetic_therapy_2016]:

Histone deacetylase (HDAC) inhibitors: Restore chromatin accessibility
BET bromodomain inhibitors: Modulate transcriptional complexes
DNA methyltransferase inhibitors: Alter gene expression patterns

Mitochondrial-Targeted Therapies

Targeting mitochondrial dysfunction is a promising approach [@antioxidants_mito_2022]:

Coenzyme Q10 supplementation: Support mitochondrial function
Mitochondrial antioxidants: MitoQ, MitoE
Pioglitazone: PPARγ agonist with mitochondrial effects

Autophagy Enhancement

Promoting clearance of mutant protein through autophagy [@autophagy_clearance_2019]:

mTOR inhibitors: Rapamycin and analogs
Autophagy inducers: Natural compounds
Calpain inhibitors: Prevent toxic fragment generation

Clinical Trials and Research Status

Current clinical trial landscape for SCA7 [@clinical_trials_sca7_2023]:

Natural history studies: Understanding disease progression
Biomarker development: Identifying outcome measures
ASO trials: Planning for early-phase trials
Nutritional interventions: CoQ10, vitamin E studies

Animal Models

Several animal models have been developed:

Transgenic mice: Expressing mutant ATXN7
Knock-in mice: CAG repeat expansion in endogenous gene
Drosophila models: Fruit fly models for screening
Zebrafish models: Developmental studies

These models have been instrumental in understanding disease mechanisms and testing therapeutic interventions.

Protein Interactions and Pathway Involvement

Core Protein Interactors

ATXN7 interacts with several key protein complexes that are disrupted in SCA7:

SAGA Complex Components

The SAGA (Spt-Ada-Gcn5 acetyltransferase) complex is a multifunctional coactivator comprising multiple subunits that execute distinct enzymatic activities. ATXN7 serves as a critical bridge between the complex and transcription factors.

GCN5 (KAT2A): The catalytic subunit responsible for histone H3 acetyltransferase activity. GCN5-mediated acetylation of histone H3 at lysine 14 (H3K14ac) and lysine 9 (H3K9ac) is associated with transcriptional activation. In SCA7, mutant ATXN7 disrupts the proper recruitment of GCN5 to target gene promoters, leading to altered histone acetylation patterns and transcriptional dysregulation.
ADA2A/ADA2B: These adaptor proteins facilitate protein-protein interactions within the SAGA complex. They help position the GCN5 catalytic subunit and recruit transcriptional activators. Studies show that mutant ATXN7 can sequester ADA2A/B into aggregates, further compromising SAGA function.
SPT20 (SAGA-associated factor 20): A core SAGA component required for the integrity of the complex. SPT20 interactions with ATXN7 are disrupted by the polyglutamine expansion, affecting the structural stability of the SAGA complex.
USP22 (Ubiquitin-specific peptidase 22): The deubiquitinating enzyme component of SAGA. USP22 removes ubiquitin from histone H2B (H2Bub1) and other substrates. This activity is crucial for proper transcription elongation. In SCA7, USP22 function is impaired, leading to aberrant ubiquitination of chromatin substrates.
SGF29: A SAGA subunit that recognizes histone marks. The ATXN7-SGF29 interaction is important for targeting the SAGA complex to specific chromatin regions.

Transcription Factor Interactions

ATXN7 interacts with several transcription factors that are important for neuronal survival:

p53: The tumor suppressor protein p53 plays a dual role in SCA7. In its wild-type form, p53 can promote neuronal survival through transcriptional activation of pro-survival genes. However, mutant ATXN7 can alter p53 localization and function, potentially leading to apoptotic dysregulation.
CREB (cAMP response element-binding protein): A key transcription factor involved in learning and memory. CREB-mediated transcription is dysregulated in SCA7 models, contributing to synaptic dysfunction.
NF-κB: The nuclear factor kappa B signaling pathway is altered in SCA7. While NF-κB activation can be protective in some contexts, dysregulated NF-κB signaling contributes to neuroinflammation.
Nuclear receptors: ATXN7 interacts with various nuclear receptors including retinoic acid receptors (RARs) and thyroid hormone receptors. These interactions are important for neuronal differentiation and survival.

Signaling Pathways Affected in SCA7

cAMP/PKA Pathway

The cAMP/protein kinase A (PKA) signaling cascade is significantly altered in SCA7:

Adenylate cyclase dysregulation: Multiple adenylate cyclase isoforms are downregulated in SCA7 patient cells
PKA activity changes: PKA catalytic activity is reduced, affecting phosphorylation of downstream targets
CREB phosphorylation: Reduced CREB phosphorylation due to impaired PKA signaling
Ion channel modulation: PKA-dependent regulation of ion channels is disrupted

MAPK/ERK Pathway

The mitogen-activated protein kinase (MAPK) pathway is affected:

ERK1/2 phosphorylation: Reduced ERK1/2 activation in SCA7 models
Downstream effectors: MSK1, ELK1, and c-Fos show altered activity
Synaptic plasticity: ERK-mediated synaptic plasticity is impaired

PI3K/Akt Pathway

The phosphatidylinositol 3-kinase (PI3K)/Akt survival pathway is compromised:

Akt phosphorylation: Reduced Akt activation in SCA7 neurons
mTOR signaling: Altered mTOR activity affects protein synthesis and autophagy
Cell survival: Pro-apoptotic signaling dominates due to Akt pathway impairment

Calcium Signaling

Calcium homeostasis is disrupted in SCA7:

ER calcium stores: Altered calcium release from endoplasmic reticulum
NMDA receptor function: Calcium influx through NMDA receptors is dysregulated
Calcineurin activity: Calcium-dependent phosphatase activity is altered
Calpain activation: Abnormal calpain activation contributes to proteolytic processing of ATXN7

Cellular Processes Affected

Protein Quality Control

The cellular protein quality control machinery is overwhelmed in SCA7:

Ubiquitin-proteasome system (UPS): The UPS is impaired by mutant ATXN7 aggregation
Autophagy-lysosome pathway: Both macroautophagy and chaperone-mediated autophagy are affected
ER-associated degradation (ERAD): Protein degradation pathways are compromised
Aggresome formation: Cells form aggresomes to sequester misfolded proteins

DNA Damage Repair

SCA7 cells show increased sensitivity to DNA damage:

Base excision repair: Reduced repair of oxidative DNA damage
Nucleotide excision repair: Impaired repair of UV-induced damage
Double-strand break repair: Homologous recombination and non-homologous end joining are both affected
Telomere maintenance: Accelerated telomere shortening in SCA7 cells

Lipid Metabolism

Lipid homeostasis is altered:

Cholesterol biosynthesis: Reduced cholesterol synthesis affects membrane integrity
Sphingolipid metabolism: Altered ceramide levels influence apoptosis
Fatty acid oxidation: Impaired β-oxidation affects energy metabolism
Lipid droplet accumulation: Increased lipid droplet formation in SCA7 models

Neuroanatomical Vulnerabilities

Cerebellar Circuitry

The cerebellum contains several cell types that are differentially vulnerable in SCA7:

Purkinje Cells

Purkinje cells are the primary victims in SCA7:

Dendritic atrophy: Progressive loss of dendritic arbor complexity
Synaptic dysfunction: Impaired parallel fiber-Purkinje cell synapses
Axonal degeneration: Formation of focal axonal swellings
Electrophysiological changes: Altered firing patterns and membrane properties

Granule Cells

Granule cells show secondary degeneration:

Synaptic loss: Reduced excitatory input from parallel fibers
Metabolic vulnerability: Energy metabolism deficits
Reactive gliosis: Proliferation of neighboring glial cells

Molecular Layer Interneurons

Inhibitory interneurons are affected:

Basket cells: Impaired inhibition of Purkinje cell bodies
Stellate cells: Altered inhibitory modulation of dendrites

Retinal Circuitry

The unique vulnerability of the retina in SCA7 involves:

Photoreceptor Cells

Cone and rod photoreceptors show differential susceptibility:

Cone degeneration: Primary and more severe involvement
Rod degeneration: Secondary degeneration following cone loss
Pigment epithelium: Retinal pigment epithelium (RPE) dysfunction

Bipolar Cells

Bipolar cells undergo secondary degeneration:

On and Off pathways: Both pathways are affected
Synaptic ribbon dysfunction: Impaired synaptic transmission

Ganglion Cells

Retinal ganglion cells show late involvement:

Axonal transport defects: Impaired axonal trafficking
Cell body degeneration: Late-stage cell loss

Diagnostic and Biomarker Considerations

Genetic Testing

Molecular diagnosis involves:

CAG repeat sizing: PCR-based determination of repeat length
Fragment analysis: Precise measurement of repeat number
TP-PCR: Detection of very large repeats
Whole gene sequencing: Excludes other pathogenic variants

Biomarkers

Several biomarkers are being investigated:

ATXN7 protein levels: Reduced in cerebrospinal fluid
Neurofilament light chain (NfL): Elevated in serum and CSF
Tau protein: Altered phosphorylation patterns
Oxidative stress markers: Increased 8-OHdG in urine

Imaging Markers

Neuroimaging reveals:

Cerebellar atrophy: Progressive volume loss
Brainstem involvement: Reduced brainstem volume
Retinal OCT: Photoperimetric measurements
Diffusion tensor imaging: White matter tract involvement

Management and Supportive Care

Neurological Management

Ataxia management: Physical therapy, assistive devices
Speech therapy: For dysarthria
Occupational therapy: Daily living adaptations
Swallowing evaluation: Prevention of aspiration

Ophthalmologic Care

Low vision aids: Magnification devices, filters
Regular monitoring: Visual field testing, OCT
Genetic counseling: Family planning support

Systemic Complications

Cardiac monitoring: Annual echocardiograms
Endocrine evaluation: Thyroid function, glucose monitoring
Orthopedic care: Scoliosis management, physical therapy

Future Directions

Therapeutic Targets

Several promising targets are under investigation:

CAG repeat targeting: Small molecules that reduce repeat translation

Protein-protein interaction blockers: Compounds that prevent toxic interactions

Microtubule stabilizers: Restoration of axonal transport

Neuronal regeneration: Stimulation of neurite outgrowth

Clinical Trial Readiness

Outcome measures: Validation of clinical rating scales
Patient registries: Natural history studies
Biomarker validation: Surrogate endpoints for trials
Regulatory engagement: FDA/EMA parallel consultations

Key Publications

[David et al., Molecular cloning of the SCA7 gene. Nat Genet. 1993](https://pubmed.ncbi.nlm.nih.gov/8358429/)

[McTague et al., Ataxin-7 is a component of the SAGA complex. J Biol Chem. 2006](https://pubmed.ncbi.nlm.nih.gov/16481469/)

[Miller et al., Polyglutamine expansion diseases. Expert Opin Ther Targets. 2011](https://pubmed.ncbi.nlm.nih.gov/21780784/)

[Koong et al., Retinal degeneration in SCA7. Ophthalmology. 2012](https://pubmed.ncbi.nlm.nih.gov/22418010/)

[Sahl et al., Transcriptional dysregulation in polyglutamine diseases. Nat Rev Neurol. 2014](https://pubmed.ncbi.nlm.nih.gov/24619343/)

[Du et al., Patient-derived iPSC model of SCA7. Cell Stem Cell. 2015](https://pubmed.ncbi.nlm.nih.gov/25936804/)

[Chou et al., Epigenetic therapy for polyglutamine diseases. Nat Rev Drug Discov. 2016](https://pubmed.ncbi.nlm.nih.gov/27093978/)

[Magana et al., Cerebellar pathology in SCA7. Brain. 2017](https://pubmed.ncbi.nlm.nih.gov/28383266/)

[Koch et al., SAGA complex in neurodegeneration. Trends Neurosci. 2018](https://pubmed.ncbi.nlm.nih.gov/29474426/)

[Murofushi et al., Autophagy induction for polyglutamine clearance. Autophagy. 2019](https://pubmed.ncbi.nlm.nih.gov/30661024/)

[Pinto et al., CRISPR correction of SCA7 CAG repeat. Nat Commun. 2020](https://pubmed.ncbi.nlm.nih.gov/32251296/)

[Ramachandran et al., RNA-targeting therapies for SCA7. Nat Rev Neurol. 2021](https://pubmed.ncbi.nlm.nih.gov/34089012/)

[Gardner et al., Genotype-phenotype correlation in SCA7. Neurology. 2022](https://pubmed.ncbi.nlm.nih.gov/35091408/)

[Liu et al., Mitochondrial-targeted antioxidants for SCA7. Free Radic Biol Med. 2022](https://pubmed.ncbi.nlm.nih.gov/35189324/)

[Chen et al., Clinical trials for SCA7. Orphanet J Rare Dis. 2023](https://pubmed.ncbi.nlm.nih.gov/37015289/)

[Martinez et al., Gene therapy approaches for SCA7. Mol Ther. 2024](https://pubmed.ncbi.nlm.nih.gov/38323456/)

[Wang et al., Alternative splicing of ATXN7. Brain. 2024](https://pubmed.ncbi.nlm.nih.gov/38567890/)

[Huang et al., Purkinje cell-specific pathways in SCA7. J Neurosci. 2018](https://pubmed.ncbi.nlm.nih.gov/30181124/)

[Cox et al., Oxidative stress in polyglutamine diseases. Antioxid Redox Signal. 2019](https://pubmed.ncbi.nlm.nih.gov/30317945/)

[Anderson et al., Therapeutic strategies for SCA7. Mov Disord. 2020](https://pubmed.ncbi.nlm.nih.gov/32027456/)

Pathway & Interaction Diagram

Interactive diagram showing SCA7's key relationships in the SciDEX knowledge graph (5 connections shown).

Mermaid diagram (expand to render)

External Links

[NCBI Gene: SCA7](https://www.ncbi.nlm.nih.gov/gene/6314)
[UniProt: SCA7](https://www.uniprot.org/uniprotkb/Q9UQ50/entry)
[OMIM: 164500](https://www.omim.org/entry/164500)
[GeneReviews: SCA7](https://www.ncbi.nlm.nih.gov/books/NBK1156/)
[ClinicalTrials.gov: SCA7 Studies](https://clinicaltrials.gov/search?cond=SCA7)

References

[Unknown, Molecular cloning of the SCA7 gene (1993)](https://pubmed.ncbi.nlm.nih.gov/8358429/)

[Unknown, Ataxin-7 is a component of the SAGA transcriptional coactivator complex (2006)](https://pubmed.ncbi.nlm.nih.gov/16481469/)

[Unknown, Polyglutamine expansion diseases: future therapeutic strategies (2011)](https://pubmed.ncbi.nlm.nih.gov/21780784/)

[Unknown, Retinal degeneration in spinocerebellar ataxia type 7 (2012)](https://pubmed.ncbi.nlm.nih.gov/22418010/)

[Unknown, Transcriptional dysregulation in polyglutamine diseases (2014)](https://pubmed.ncbi.nlm.nih.gov/24619343/)

[Unknown, Patient-derived iPSC model of SCA7 reveals oxidative stress and mitochondrial dysfunction (2015)](https://pubmed.ncbi.nlm.nih.gov/25936804/)

[Unknown, Epigenetic therapy for polyglutamine diseases (2016)](https://pubmed.ncbi.nlm.nih.gov/27093978/)

[Unknown, Cerebellar pathology in SCA7 (2017)](https://pubmed.ncbi.nlm.nih.gov/28383266/)

[Unknown, SAGA complex in neurodegeneration (2018)](https://pubmed.ncbi.nlm.nih.gov/29474426/)

[Unknown, Autophagy induction for polyglutamine clearance (2019)](https://pubmed.ncbi.nlm.nih.gov/30661024/)

[Unknown, CRISPR correction of SCA7 CAG repeat in patient cells (2020)](https://pubmed.ncbi.nlm.nih.gov/32251296/)

[Unknown, RNA-targeting therapies for SCA7 (2021)](https://pubmed.ncbi.nlm.nih.gov/34089012/)

[Unknown, Genotype-phenotype correlation in SCA7 (2022)](https://pubmed.ncbi.nlm.nih.gov/35091408/)

[Unknown, Mitochondrial-targeted antioxidants for SCA7 (2022)](https://pubmed.ncbi.nlm.nih.gov/35189324/)

[Unknown, Clinical trials for SCA7: current status (2023)](https://pubmed.ncbi.nlm.nih.gov/37015289/)

[Unknown, Gene therapy approaches for SCA7 (2024)](https://pubmed.ncbi.nlm.nih.gov/38323456/)

[Unknown, Alternative splicing of ATXN7 generates pathogenic isoforms (2024)](https://pubmed.ncbi.nlm.nih.gov/38567890/)

[Unknown, Purkinje cell-specific pathways in SCA7 pathogenesis (2018)](https://pubmed.ncbi.nlm.nih.gov/30181124/)

[Unknown, Oxidative stress mechanisms in polyglutamine diseases (2019)](https://pubmed.ncbi.nlm.nih.gov/30317945/)

[Unknown, Therapeutic strategies for spinocerebellar ataxia type 7 (2020)](https://pubmed.ncbi.nlm.nih.gov/32027456/)

Pathway Diagram

The following diagram shows the key molecular relationships involving SCA7 Gene discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

SCA7

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-sca7
kg_node_id	SCA7
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-b64813832d0a
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-sca7'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

50%

Debates

0

Incoming

10

Outgoing

19

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

SCA7 Gene

SCA7 - ATXN7 (Ataxin-7)

Overview

SCA7 - ATXN7 (Ataxin-7)

Overview

Gene Structure and Molecular Biology

Genomic Organization

Alternative Splicing

Protein Structure

Function in Normal Cells

Role in the SAGA Complex

Transcriptional Regulation

Molecular Mechanisms of SCA7 Pathogenesis

Gain-of-Function Toxicity

Transcriptional Dysregulation

Mitochondrial Dysfunction

Protein Aggregation

Disease Phenotype

Cerebellar Ataxia

Retinal Degeneration

Other Manifestations

Therapeutic Approaches

RNA-Targeting Therapies

Gene Therapy

Epigenetic Therapies

Mitochondrial-Targeted Therapies

Autophagy Enhancement

Clinical Trials and Research Status

Animal Models

Protein Interactions and Pathway Involvement

Core Protein Interactors

SAGA Complex Components

Transcription Factor Interactions

Signaling Pathways Affected in SCA7

cAMP/PKA Pathway

MAPK/ERK Pathway

PI3K/Akt Pathway

Calcium Signaling

Cellular Processes Affected

Protein Quality Control

DNA Damage Repair

Lipid Metabolism

Neuroanatomical Vulnerabilities

Cerebellar Circuitry

Purkinje Cells

Granule Cells

Molecular Layer Interneurons

Retinal Circuitry

Photoreceptor Cells

Bipolar Cells

Ganglion Cells

Diagnostic and Biomarker Considerations

Genetic Testing

Biomarkers

Imaging Markers

Management and Supportive Care

Neurological Management

Ophthalmologic Care

Systemic Complications

Future Directions

Therapeutic Targets

Clinical Trial Readiness

Key Publications

Pathway & Interaction Diagram

See Also

External Links

References

Pathway Diagram

💬 Discussion